Condition (MeSH)
Pachyonychia Congenita
ClinicalTrials.gov lists 12 trials for Pachyonychia Congenita or a narrower condition beneath it. Palvella Therapeutics, Inc. has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Pachyonychia Congenita itself; the rest are tagged with a narrower condition beneath it.
When did Pachyonychia Congenita trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2011 | 1 |
| 2008 | 1 |
| 2004 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pachyonychia Congenita trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Not applicable | 1 |
| Observational | 1 |
How many Pachyonychia Congenita trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 8 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pachyonychia Congenita trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Palvella Therapeutics, Inc. | 4 |
| Orvida Pharma (formerly Kamari Pharma) | 2 |
| Tel-Aviv Sourasky Medical Center | 1 |
| TransDerm, Inc. | 1 |
Which drugs are being tested for Pachyonychia Congenita? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Jojoba oil (placebo) | 1 |
| SIMVASTATIN | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| PTX-022 | 3 |
| Vital signs | 2 |
| Jojoba oil with broccoli sprout extract | 1 |
| TD101 | 1 |
| KM-001 1% cream 16 weeks treatment | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Pachyonychia Congenita? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pachyonychia congenita in pediatric patients: natural history, features, and impact. | JAMA dermatology | 2014 | Yes |
| The molecular genetic analysis of the expanding pachyonychia congenita case collection. | The British journal of dermatology | 2014 | Yes |
| A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. | Journal of the American Academy of Dermatology | 2012 | Yes |
| The phenotypic and molecular genetic features of pachyonychia congenita. | The Journal of investigative dermatology | 2011 | Yes |
| Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. | Journal of dermatological science | 2009 | Yes |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Pachyonychia congenita | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Pachyonychia congenita | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Pachyonychia congenita | Cases families | Worldwide | Not stated | Exact | |
| Pachyonychia congenita | Cases families | Worldwide | Not stated | Unspecified | |
| Pachyonychia congenita | Cases families | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Pachyonychia congenita | 2309 | Exact | Orphadata Science knowledge files, Product 1 |
| Pachyonychia congenita | 2309 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.